Login to VeloClub|Not a member?   Sign up now.

Ulissi wins in Turkey to take lead, Yates best in Iran: Daily News Digest

by Shane Stokes

October 14, 2017

Ulissi wins stage 4 of the Presidential Tour of Turkey; Yates wins final stage of the Tour of Iran; Lappartient plans to ban use of corticoids from early 2019; INRNG on the Nudge Theory and Tramadol; Archbold signs for Aqua Blue Sport; Dombrowski to rethink approach after disappointing season; Williams re-signs with Orica-Scott; Twenty20 announces first new signee in Clyne; WaowDeals Pro Cycling signs Van De Ree and Rooijakkers; VeloNews bought by previous owner Felix Magowan plus partners; See.Sense enjoys more crowdfunding success for its next intelligent light; Battle Mountain set for community screenings release; Video: Two lives saved by one bicycle; Video: Bringing the family along for the ride.

Lappartient plans to ban use of corticoids from early 2019

by Shane Stokes

New UCI president David Lappartient has said that he has set a start date of the beginning of the 2019 season as the point from which he will ban the use of corticoids by riders. Speaking to Sporza, he indicated the mechanism by which he will do that.

“I want to put those products on the list of prohibited resources,” he said, referring to the use of the substance, which has performance-enhancing properties. “Even though that is not the case [it is not currently on WADA’s banned list – ed.], we can also improve our approach in cycling.

“For example, by taking a rider out [of races] for the use of cortisone. Not for a positive doping case, but for the health of the rider himself. We can then impose a temporary start ban. For example, the rider is left out for 15 days and returns when everything is back in order. I would like to introduce that from the beginning of 2019.”

The approach is in line with the rules of the MPCC anti-doping organisation, which imposes an eight-day no-start rule following the use of cortisone. It means that riders of MPCC member teams cannot use related TUEs in competition, such as was done by Bradley Wiggins in 2011, 2012 and 2013. Wiggins won the 2012 Tour while using triamcinolone acetonide, being able to take the substance due to a medical certificate which green-lighted its use.

Other riders such as David Millar, Michael Rasmussen and Jorg Jaksche said that they deliberately acquired TUE certificates to use the substance to boost their performance. It improves physical capabilities while also helping riders to lose weight.

Click through to read more at CyclingTips.

BACK TO TOP
15 NEW ARTICLES